Answers are grounded in this paper and cite their sources.
). Tumour growth was analysed longitudinally, metastatic burden assessed by hCD44-positive micrometastasis enumeration, and pharmacodynamic responses evaluated through Ki-67 indexes, necrotic fractions, and Gli1 expression. Neither DTX alone, ITZ alone, nor their combination reduced primary tumour growth or cumulative tumour burden. However, the combination suppressed development of lung micrometastases in both models. ITZ and DTX + ITZ reduced Ki-67 and Gli1 levels, demonstrating inhibition of proliferation and Hedgehog signalling despite the absence of tumour shrinkage. ITZ monotherapy was well tolerated, whereas DTX-containing regimens produced expected systemic toxicity. These results indicate antimetastatic and pathway-modulating activity of ITZ in resistant prostate cancer and support its further evaluation as a rational adjunct to taxanes in treatment contexts where metastatic control is a key therapeutic objective.
No takes yet. Share an insight, caveat, or question.
Souza et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: